<!doctype html><!-- This site was created with Wowchemy. https://www.wowchemy.com --><!-- Last Published: 2023. május 11. --><html lang=hu><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=generator content="Wowchemy 5.7.0 for Hugo"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=preload as=style href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap"><link rel=stylesheet href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap" media=print onload='this.media="all"'><link rel=stylesheet href=/css/vendor-bundle.min.16f785cdb553c8c4431db6775122af35.css media=print onload='this.media="all"'><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/academicons@1.9.2/css/academicons.min.css integrity="sha512-KlJCpRsLf+KKu2VQa5vmRuClRFjxc5lXO03ixZt82HZUk41+1I0bD8KBSA0fY290ayMfWYI9udIqeOWSu1/uZg==" crossorigin=anonymous media=print onload='this.media="all"'><link rel=stylesheet href=/css/wowchemy.0f229d4b7ebad1917a9a357cba2effab.css><link rel=stylesheet href=/css/libs/chroma/github-light.min.css title=hl-light media=print onload='this.media="all"'><link rel=stylesheet href=/css/libs/chroma/dracula.min.css title=hl-dark media=print onload='this.media="all"' disabled><meta name=author content="Ferenci Tamás"><meta name=description content="Describe the characteristics, management and outcomes of hospitalized ST-segment elevation myocardial infarction (STEMI) patients according to national ongoing myocardial infarction registries in Estonia, Hungary, Norway, and Sweden.Country-level aggregated data was used to study baseline characteristics, use of in-hospital procedures, medications at discharge, in-hospital complications, 30-day and 1-year mortality for all patients admitted with STEMI during 2014–2017 using data from EMIR (Estonia; n = 4584), HUMIR (Hungary; n = 23 685), NORMI (Norway; n = 12 414, data for 2013–2016), and SWEDEHEART (Sweden; n = 23 342). Estonia and Hungary had a higher proportion of women, patients with hypertension, diabetes, and peripheral artery disease compared to Norway and Sweden. Rates of reperfusion varied from 75.7% in Estonia to 84.0% in Sweden. Rates of recommendation of discharge medications were generally high and similar. However, Estonia demonstrated the lowest rates of dual antiplatelet therapy (78.1%) and statins (86.5%). Norway had the lowest rates of beta-blockers (80.5%) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (61.5%). The 30-day mortality rates ranged between 9.9% and 13.4% remaining lowest in Sweden. One-year mortality rates ranged from 14.8% in Sweden and 16.0% in Norway to 20.6% in Hungary and 21.1% in Estonia. Age-adjusted lethality rates were highest for Hungary and lowest for Sweden.This inter-country comparison of data from four national ongoing European registries provides new insights into the risk factors, management and outcomes of patients with STEMI. There are several possible reasons for the findings, including coverage of the registries and variability of baseline-characteristics’ definitions that need to be further explored."><link rel=alternate hreflang=hu href=https://www.medstat.hu/publication/mtmt-31937161/><link rel=canonical href=https://www.medstat.hu/publication/mtmt-31937161/><link rel=manifest href=/manifest.webmanifest><link rel=icon type=image/png href=/media/icon_hu577da21a7a63fbc8612c74418210a2c7_11440_32x32_fill_lanczos_center_3.png><link rel=apple-touch-icon type=image/png href=/media/icon_hu577da21a7a63fbc8612c74418210a2c7_11440_180x180_fill_lanczos_center_3.png><meta name=theme-color content="#1565c0"><meta property="twitter:card" content="summary_large_image"><meta property="twitter:site" content="@wowchemy"><meta property="twitter:creator" content="@wowchemy"><meta property="twitter:image" content="https://www.medstat.hu/media/sharing.png"><meta property="og:site_name" content="Ferenci Tamás honlapja"><meta property="og:url" content="https://www.medstat.hu/publication/mtmt-31937161/"><meta property="og:title" content="Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway, and Sweden according to national ongoing registries | Ferenci Tamás honlapja"><meta property="og:description" content="Describe the characteristics, management and outcomes of hospitalized ST-segment elevation myocardial infarction (STEMI) patients according to national ongoing myocardial infarction registries in Estonia, Hungary, Norway, and Sweden.Country-level aggregated data was used to study baseline characteristics, use of in-hospital procedures, medications at discharge, in-hospital complications, 30-day and 1-year mortality for all patients admitted with STEMI during 2014–2017 using data from EMIR (Estonia; n = 4584), HUMIR (Hungary; n = 23 685), NORMI (Norway; n = 12 414, data for 2013–2016), and SWEDEHEART (Sweden; n = 23 342). Estonia and Hungary had a higher proportion of women, patients with hypertension, diabetes, and peripheral artery disease compared to Norway and Sweden. Rates of reperfusion varied from 75.7% in Estonia to 84.0% in Sweden. Rates of recommendation of discharge medications were generally high and similar. However, Estonia demonstrated the lowest rates of dual antiplatelet therapy (78.1%) and statins (86.5%). Norway had the lowest rates of beta-blockers (80.5%) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (61.5%). The 30-day mortality rates ranged between 9.9% and 13.4% remaining lowest in Sweden. One-year mortality rates ranged from 14.8% in Sweden and 16.0% in Norway to 20.6% in Hungary and 21.1% in Estonia. Age-adjusted lethality rates were highest for Hungary and lowest for Sweden.This inter-country comparison of data from four national ongoing European registries provides new insights into the risk factors, management and outcomes of patients with STEMI. There are several possible reasons for the findings, including coverage of the registries and variability of baseline-characteristics’ definitions that need to be further explored."><meta property="og:image" content="https://www.medstat.hu/media/sharing.png"><meta property="og:locale" content="hu"><meta property="article:published_time" content="2023-04-10T18:20:05+00:00"><meta property="article:modified_time" content="2023-04-10T20:20:05+02:00"><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://www.medstat.hu/publication/mtmt-31937161/"},"headline":"Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway, and Sweden according to national ongoing registries","datePublished":"2023-04-10T18:20:05Z","dateModified":"2023-04-10T20:20:05+02:00","author":{"@type":"Person","name":"Mai Blöndal"},"publisher":{"@type":"Organization","name":"Ferenci Tamás honlapja","logo":{"@type":"ImageObject","url":"https://www.medstat.hu/media/icon_hu577da21a7a63fbc8612c74418210a2c7_11440_192x192_fill_lanczos_center_3.png"}},"description":"Describe the characteristics, management and outcomes of hospitalized ST-segment elevation myocardial infarction (STEMI) patients according to national ongoing myocardial infarction registries in Estonia, Hungary, Norway, and Sweden.Country-level aggregated data was used to study baseline characteristics, use of in-hospital procedures, medications at discharge, in-hospital complications, 30-day and 1-year mortality for all patients admitted with STEMI during 2014–2017 using data from EMIR (Estonia; n = 4584), HUMIR (Hungary; n = 23 685), NORMI (Norway; n = 12 414, data for 2013–2016), and SWEDEHEART (Sweden; n = 23 342). Estonia and Hungary had a higher proportion of women, patients with hypertension, diabetes, and peripheral artery disease compared to Norway and Sweden. Rates of reperfusion varied from 75.7% in Estonia to 84.0% in Sweden. Rates of recommendation of discharge medications were generally high and similar. However, Estonia demonstrated the lowest rates of dual antiplatelet therapy (78.1%) and statins (86.5%). Norway had the lowest rates of beta-blockers (80.5%) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (61.5%). The 30-day mortality rates ranged between 9.9% and 13.4% remaining lowest in Sweden. One-year mortality rates ranged from 14.8% in Sweden and 16.0% in Norway to 20.6% in Hungary and 21.1% in Estonia. Age-adjusted lethality rates were highest for Hungary and lowest for Sweden.This inter-country comparison of data from four national ongoing European registries provides new insights into the risk factors, management and outcomes of patients with STEMI. There are several possible reasons for the findings, including coverage of the registries and variability of baseline-characteristics’ definitions that need to be further explored."}</script><title>Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway, and Sweden according to national ongoing registries | Ferenci Tamás honlapja</title></head><body id=top data-spy=scroll data-offset=70 data-target=#TableOfContents class=page-wrapper data-wc-page-id=a7888d0c716fd2973ce12f76685eb9c1><script src=/js/wowchemy-init.min.ec9d49ca50e4b80bdb08f0417a28ed84.js></script><aside class=search-modal id=search><div class=container><section class=search-header><div class="row no-gutters justify-content-between mb-3"><div class=col-6><h1>Keresés</h1></div><div class="col-6 col-search-close"><a class=js-search href=# aria-label=Close><i class="fas fa-times-circle text-muted" aria-hidden=true></i></a></div></div><div id=search-box><input name=q id=search-query placeholder=Keresés... autocapitalize=off autocomplete=off autocorrect=off spellcheck=false type=search class=form-control aria-label=Keresés...></div></section><section class=section-search-results><div id=search-hits></div></section></div></aside><div class="page-header header--fixed"><header><nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id=navbar-main><div class=container-xl><div class="d-none d-lg-inline-flex"><a class=navbar-brand href=/>Ferenci Tamás honlapja</a></div><button type=button class=navbar-toggler data-toggle=collapse data-target=#navbar-content aria-controls=navbar-content aria-expanded=false aria-label=Navigáció>
<span><i class="fas fa-bars"></i></span></button><div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none"><a class=navbar-brand href=/>Ferenci Tamás honlapja</a></div><div class="navbar-collapse main-menu-item collapse justify-content-start" id=navbar-content><ul class="navbar-nav d-md-inline-flex"><li class=nav-item><a class=nav-link href=/#about><span>Rólam</span></a></li><li class=nav-item><a class=nav-link href=/#oktatas><span>Oktatás</span></a></li><li class=nav-item><a class=nav-link href=/#projektek><span>Projektjeim</span></a></li><li class=nav-item><a class=nav-link href=/#esszek><span>Esszéim</span></a></li><li class=nav-item><a class=nav-link href=/#publications><span>Cikkek</span></a></li><li class=nav-item><a class=nav-link href=/#contact><span>Kapcsolat</span></a></li></ul></div><ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2"><li class=nav-item><a class="nav-link js-search" href=# aria-label=Keresés><i class="fas fa-search" aria-hidden=true></i></a></li><li class="nav-item dropdown theme-dropdown"><a href=# class=nav-link data-toggle=dropdown aria-haspopup=true aria-label="Display preferences"><i class="fas fa-moon" aria-hidden=true></i></a><div class=dropdown-menu><a href=# class="dropdown-item js-set-theme-light"><span>Light</span></a>
<a href=# class="dropdown-item js-set-theme-dark"><span>Dark</span></a>
<a href=# class="dropdown-item js-set-theme-auto"><span>Automatic</span></a></div></li></ul></div></nav></header></div><div class=page-body><div class=pub><div class="article-container pt-3"><h1>Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway, and Sweden according to national ongoing registries</h1><div class=article-metadata><div><span>Mai Blöndal</span>, <span>Tiia Ainla</span>, <span>Jaan Eha</span>, <span>Piret Lõiveke</span>, <span>Toomas Marandi</span>, <span>Aet Saar</span>, <span>Gudrun Veldre</span>, <span>Robert Edfors</span>, <span>Christian Lewinter</span>, <span>Tomas Jernberg</span>, <span>Jarle Jortveit</span>, <span>Sigrun Halvorsen</span>, <span>Dávid Becker</span>, <span>Zoltán Csanádi</span>, <span>Tamás Ferenci</span>, <span>Péter Andréka</span>, <span>András Jánosi</span></div><span class=article-date>január, 2022</span></div><div class="btn-links mb-3"><a href=# class="btn btn-outline-primary btn-page-header js-cite-modal" data-filename=/publication/mtmt-31937161/cite.bib>Idézet</a>
<a class="btn btn-outline-primary btn-page-header" href=https://doi.org/10.1093/ehjqcco/qcaa098 target=_blank rel=noopener>DOI</a>
<a class="btn btn-outline-primary btn-page-header" href=https://m2.mtmt.hu/api/publication/31937161 target=_blank rel=noopener>URL</a></div></div><div class=article-container><h3>Kivonat</h3><p class=pub-abstract>Describe the characteristics, management and outcomes of hospitalized ST-segment elevation myocardial infarction (STEMI) patients according to national ongoing myocardial infarction registries in Estonia, Hungary, Norway, and Sweden.Country-level aggregated data was used to study baseline characteristics, use of in-hospital procedures, medications at discharge, in-hospital complications, 30-day and 1-year mortality for all patients admitted with STEMI during 2014–2017 using data from EMIR (Estonia; n = 4584), HUMIR (Hungary; n = 23 685), NORMI (Norway; n = 12 414, data for 2013–2016), and SWEDEHEART (Sweden; n = 23 342). Estonia and Hungary had a higher proportion of women, patients with hypertension, diabetes, and peripheral artery disease compared to Norway and Sweden. Rates of reperfusion varied from 75.7% in Estonia to 84.0% in Sweden. Rates of recommendation of discharge medications were generally high and similar. However, Estonia demonstrated the lowest rates of dual antiplatelet therapy (78.1%) and statins (86.5%). Norway had the lowest rates of beta-blockers (80.5%) and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (61.5%). The 30-day mortality rates ranged between 9.9% and 13.4% remaining lowest in Sweden. One-year mortality rates ranged from 14.8% in Sweden and 16.0% in Norway to 20.6% in Hungary and 21.1% in Estonia. Age-adjusted lethality rates were highest for Hungary and lowest for Sweden.This inter-country comparison of data from four national ongoing European registries provides new insights into the risk factors, management and outcomes of patients with STEMI. There are several possible reasons for the findings, including coverage of the registries and variability of baseline-characteristics’ definitions that need to be further explored.</p><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Típus</div><div class="col-12 col-md-9"><a href=/publication/#2>Journal article</a></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Publikáció</div><div class="col-12 col-md-9"><em>EUROPEAN HEART JOURNAL - QUALITY OF CARE AND CLINICAL OUTCOMES</em></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=space-below></div><div class=article-style></div><div class=article-tags><a class="badge badge-light" href=/tag/mortality-real-world-evidence-st-segment-elevation-myocardial-infarction-registry-study/>MORTALITY; Real-world evidence; ST-segment elevation myocardial infarction; Registry study</a></div><div class=share-box><ul class=share><li><a href="mailto:?subject=Comparison%20of%20management%20and%20outcomes%20of%20ST-segment%20elevation%20myocardial%20infarction%20patients%20in%20Estonia%2C%20Hungary%2C%20Norway%2C%20and%20Sweden%20according%20to%20national%20ongoing%20registries&amp;body=https%3A%2F%2Fwww.medstat.hu%2Fpublication%2Fmtmt-31937161%2F" target=_blank rel=noopener class=share-btn-email aria-label=envelope><i class="fas fa-envelope"></i></a></li><li><a href="https://www.facebook.com/sharer.php?u=https%3A%2F%2Fwww.medstat.hu%2Fpublication%2Fmtmt-31937161%2F&amp;t=Comparison+of+management+and+outcomes+of+ST-segment+elevation+myocardial+infarction+patients+in+Estonia%2C+Hungary%2C+Norway%2C+and+Sweden+according+to+national+ongoing+registries" target=_blank rel=noopener class=share-btn-facebook aria-label=facebook><i class="fab fa-facebook"></i></a></li><li><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.medstat.hu%2Fpublication%2Fmtmt-31937161%2F&amp;text=Comparison+of+management+and+outcomes+of+ST-segment+elevation+myocardial+infarction+patients+in+Estonia%2C+Hungary%2C+Norway%2C+and+Sweden+according+to+national+ongoing+registries" target=_blank rel=noopener class=share-btn-twitter aria-label=twitter><i class="fab fa-twitter"></i></a></li><li><a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fwww.medstat.hu%2Fpublication%2Fmtmt-31937161%2F&amp;title=Comparison+of+management+and+outcomes+of+ST-segment+elevation+myocardial+infarction+patients+in+Estonia%2C+Hungary%2C+Norway%2C+and+Sweden+according+to+national+ongoing+registries" target=_blank rel=noopener class=share-btn-linkedin aria-label=linkedin-in><i class="fab fa-linkedin-in"></i></a></li><li><a href="https://reddit.com/submit?url=https%3A%2F%2Fwww.medstat.hu%2Fpublication%2Fmtmt-31937161%2F&amp;title=Comparison+of+management+and+outcomes+of+ST-segment+elevation+myocardial+infarction+patients+in+Estonia%2C+Hungary%2C+Norway%2C+and+Sweden+according+to+national+ongoing+registries" target=_blank rel=noopener class=share-btn-reddit aria-label=reddit-alien><i class="fab fa-reddit-alien"></i></a></li></ul></div></div></div></div><div class=page-footer><div class=container><footer class=site-footer><p class="powered-by copyright-license-text">© 2023 Ferenci Tamás. This work is licensed under <a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank>CC BY NC ND 4.0</a></p><p class="powered-by footer-license-icons"><a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank aria-label="Creative Commons"><i class="fab fa-creative-commons fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-by fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nc fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nd fa-2x" aria-hidden=true></i></a></p><p class=powered-by>Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target=_blank rel=noopener>Wowchemy</a> — the free, <a href=https://github.com/wowchemy/wowchemy-hugo-themes target=_blank rel=noopener>open source</a> website builder that empowers creators.</p></footer></div></div><script src=/js/vendor-bundle.min.d26509351aa0ff874abbee824e982e9b.js></script>
<script id=search-hit-fuse-template type=text/x-template>
    <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
    </div>
  </script><script src=https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin=anonymous></script>
<script id=page-data type=application/json>{"use_headroom":true}</script><script src=/js/wowchemy-headroom.db4755770454eb63685f8de785c0a172.js type=module></script>
<script src=/hu/js/wowchemy.min.4d23fe86388c1f4ad1e72b6d8a853e3c.js></script><div id=modal class="modal fade" role=dialog><div class=modal-dialog><div class=modal-content><div class=modal-header><h5 class=modal-title>Idézet</h5><button type=button class=close data-dismiss=modal aria-label=Close>
<span aria-hidden=true>&#215;</span></button></div><div class=modal-body><pre><code></code></pre></div><div class=modal-footer><a class="btn btn-outline-primary my-1 js-copy-cite" href=# target=_blank><i class="fas fa-copy"></i> Másolat</a>
<a class="btn btn-outline-primary my-1 js-download-cite" href=# target=_blank><i class="fas fa-download"></i> Letöltés</a><div id=modal-error></div></div></div></div></div><script src=/js/wowchemy-publication.68f8d7090562ca65fc6d3cb3f8f2d2cb.js type=module></script>
<script type=text/javascript>var sc_project=8274576,sc_invisible=1,sc_security="b688857d"</script><script type=text/javascript src=https://www.statcounter.com/counter/counter.js async></script><noscript><div class=statcounter><a title="ingyenes
webstatisztika" href=https://www.statcounter.hu/ target=_blank><img class=statcounter src=https://c.statcounter.com/8274576/0/b688857d/1/ alt="ingyenes webstatisztika" referrerpolicy=no-referrer-when-downgrade></a></div></noscript></body></html>